Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (abre uma nova janela)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fonte‎: Cancer 2013;119(21):3784-7.

Indexado‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (abre uma nova janela)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (abre uma nova janela)

Chakrabarti S, Varma S, Singh S, Kumari S

Fonte‎: Eur J Haematol 1998;60(5):313-4.

Indexado‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (abre uma nova janela)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (abre uma nova janela)

Delaney M, Matthews DC, Gernsheimer TB

Fonte‎: Pediatr Blood Cancer 2017;64(12):e26641.

Indexado‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (abre uma nova janela)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (abre uma nova janela)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Fonte‎: J Urol 2010;184(3):1152-7.

Indexado‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (abre uma nova janela)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (abre uma nova janela)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fonte‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indexado‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (abre uma nova janela)

Pediatric off-label use of recombinant factor VIIa. (abre uma nova janela)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Fonte‎: Pediatrics 2009;123(3):1066-72.

Indexado‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (abre uma nova janela)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (abre uma nova janela)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Fonte‎: Indian J Pediatr 2011;78(8):961-8.

Indexado‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (abre uma nova janela)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (abre uma nova janela)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fonte‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indexado‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (abre uma nova janela)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (abre uma nova janela)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Fonte‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Indexado‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (abre uma nova janela)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (abre uma nova janela)

Das P, Carcao M, Hitzler J

Fonte‎: Pediatr Blood Cancer 2006;47(2):206-9.

Indexado‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (abre uma nova janela)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (abre uma nova janela)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Fonte‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Indexado‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (abre uma nova janela)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (abre uma nova janela)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Fonte‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Indexado‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (abre uma nova janela)

Off-label use of recombinant factor VIIa in pediatric patients. (abre uma nova janela)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Fonte‎: Pediatrics 2012;129(6):e1533-40.

Indexado‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (abre uma nova janela)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (abre uma nova janela)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Fonte‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Indexado‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (abre uma nova janela)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (abre uma nova janela)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fonte‎: Med Oncol 2010;27(1):16-9.

Indexado‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (abre uma nova janela)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (abre uma nova janela)

Ucar C, Caliskan U

Fonte‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Indexado‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (abre uma nova janela)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (abre uma nova janela)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Fonte‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indexado‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (abre uma nova janela)

The use of DDAVP in children with bleeding disorders. (abre uma nova janela)

Ben-Ami T, Revel-Vilk S

Fonte‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Indexado‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (abre uma nova janela)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (abre uma nova janela)

Kobrinsky NL, Tulloch H

Fonte‎: J Pediatr 1988;112(6):993-6.

Indexado‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (abre uma nova janela)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (abre uma nova janela)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Fonte‎: J Pediatr Surg 2013;48(3):689-94.

Indexado‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (abre uma nova janela)